Table 1 Main features of all included studies for diagnosis and prognosis
Id | lncRNAs | Author | Year | Country | Duration of research | Number of Patients (high/low) | Sum of Patients | Expression in Tumor | Internal reference | Method | Cut-off | Quality Score | Follow-up (Month) | Sample | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | TMED11P | Zhenfei Zhu | 2016 | China | 2007–2013 | 21/57 | 78 | Down-regulation | U6 | qRT-PCR | Median | 7 | 60 | Tissue | OS |
2 | LOC389641 | Shangyou Zheng | 2015 | China | 2008–2015 | 53/53 | 106 | Up-regulation | GAPDH | qRT-PCR | Median | 8 | 72 | Tissue | OS |
6 | HMlincRNA717 | X.L.SUN | 2016 | China | 2005–2011 | 74/76 | 150 | Down-regulation | U6 | qRT-PCR | Median | 7 | 70 | Tissue | OS |
7 | ATB | Shibin Qu | 2015 | China | No | 75/75 | 150 | Down-regulation | β-Actin | qRT-PCR | Median | 8 | 60 | Tissue | OS |
8 | CCDC26 | Wei Peng | 2016 | China | 2011–2015 | 20/20 | 40 | Up-regulation | GAPDH | qRT-PCR | Median | 7 | 60 | Tissue | OS |
9 | uc.345 | Chao Liu | 2016 | China | 2011–2013 | 68/35 | 103 | Up-regulation | RNU6B | qRT-PCR | Median | 6 | 50 | Tissue | OS |
11 | Linc-pint | Le Li | 2016 | China | 2008–2011 | 28/23 | 51 | Down-regulation | GAPDH | qRT-PCR | Median | 8 | 60 | Plasma | OS |
17 | AFAP1-AS1 | Xue-Liang Fu | 2016 | China | 2012–2014 | 40/40 | 80 | Up-regulation | GAPDH | qRT-PCR | Median | 8 | 50–60 | Tissue | OS |
17 | UCA1 | Xue-Liang Fu | 2016 | China | 2012–2014 | 40/40 | 80 | Up-regulation | GAPDH | qRT-PCR | Median | 8 | 50–60 | Tissue | OS |
17 | ENSG00000218510 | Xue-Liang Fu | 2016 | China | 2012–2014 | 40/40 | 80 | Down-regulation | GAPDH | qRT-PCR | Median | 8 | 50–60 | Tissue | OS |
17 | CRNDE | Xue-Liang Fu | 2016 | China | 2012–2014 | 40/40 | 80 | Up-regulation | GAPDH | qRT-PCR | Median | 8 | 50–60 | Tissue | OS |
17 | NR_036488 | Xue-Liang Fu | 2016 | China | 2012–2014 | 40/40 | 80 | Up-regulation | GAPDH | qRT-PCR | Median | 8 | 50–60 | Tissue | OS |
17 | ENSG00000244649 | Xue-Liang Fu | 2016 | China | 2012–2014 | 40/40 | 80 | Up-regulation | GAPDH | qRT-PCR | Median | 8 | 50–60 | Tissue | OS |
18 | UCA1 | Ping Chen | 2016 | China | 2006–2009 | 64/64 | 128 | Up-regulation | GAPDH | qRT-PCR | Mean | 8 | 60 | Tissue | OS |
23 | HOTTIP-005 | Yingxue Wang | 2015 | China | 2006–2014 | 118/26 | 144 | Up-regulation | GAPDH & β-Actin | qRT-PCR | Median | 8 | 60 | Tissue | OS |
23 | XLOC_006390 | Yingxue Wang | 2015 | China | 2006–2014 | 110/34 | 144 | Up-regulation | GAPDH & β-Actin | qRT-PCR | Median | 8 | 60 | Tissue | OS |
23 | RP11-567G11.1 | Yingxue Wang | 2015 | China | 2006–2014 | 96/48 | 144 | Up-regulation | GAPDH & β-Actin | qRT-PCR | Median | 8 | 60 | Tissue | OS |
24 | MALAT1 | Er-Jun Pang | 2014 | China | No | 63/63 | 126 | Up-regulation | β-Actin | qRT-PCR | Median | 7 | 60 | Tissue | OS |
38 | ENST00000480739 | Y-W Sun | 2014 | China | No | 20/15 | 35 | Down-regulation | β-Actin | qRT-PCR | Median | 8 | 30 | Tissue | OS |
39 | HULC | Wei Peng | 2014 | China | 2006–2010 | 212/92 | 304 | Up-regulation | GAPDH | qRT-PCR | No | 7 | 60 | Tissue | OS |
40 | MALAT1 | Jiang-Hua Liu | 2014 | China | 2010–2011 | 26/19 | 45 | Up-regulation | GAPDH | qRT-PCR | Mean | 8 | 40 | Tissue | DSS |
41 | BC008363 | Jiao Li | 2014 | China | 2009- 2010 | 17/13 | 30 | Down-regulation | GAPDH | qRT-PCR | Median | 8 | 30 | Tissue | OS |
43 | LOC285194 | Yue-Chao Ding | 2014 | China | 2004–2009 | 45/40 | 85 | Down-regulation | GAPDH | qRT-PCR | Mean | 6 | 60 | Tissue | |
50 | C/EBPb | Chen-Song Huang | 2017 | China | 2008–2013 | 54/29 | 83 | Up-regulation | NO | qRT-PCR | Mean | 7 | 100 | Tissue | OS/DFS |
50 | LINC01133 | Chen-Song Huang | 2018 | China | 2015–2017 | 88/89 | 177 | Up-regulation | NO | qRT-PCR | Mean | 8 | 100 | Tissue | OS/DFS |
59 | DUXAP8 | Yifan Lian | 2018 | China | 2007–2012 | 29/29 | 58 | Up-regulation | GAPDH | qRT-PCR | median | 7 | 60 | Tissue | OS |
67 | CASC2 | Yaqun Yu | 2017 | China | No | 56/54 | 110 | Down-regulated | RNU6B | qRT-PCR | Median | 7 | 48 | Tissue | OS |
76 | DANCR | Lei Chen | 2018 | China | No | 86/120 | 206 | Up-regulation | GAPDH | qRT-PCR | Mean | 8 | 72 | Tissue | OS/PFS |
83 | LINC00346 | Wan-Xin Peng | 2019 | China | No | 46/131 | 177 | Up-regulation | GAPDH | qRT-PCR | No | 4 | 80 | Tissue | OS |
103 | XIST | Wei Wei | 2017 | China | No | 32/32 | 64 | Up-regulation | RNU6B | qRT-PCR | Median | 8 | 30 | Tissue | OS |
109 | ABHD11-AS1 | X. QIAO | 2018 | China | 2010–2013 | 72/75 | 147 | Up-regulation | GAPDH | qRT-PCR | No | 8 | 60 | Tissue | OS |
112 | DLEU1 | Song Gao | 2018 | China | 2012–2017 | 39/23 | 62 | Up-regulation | GAPDH | qRT-PCR | Median | 8 | 60 | Tissue | OS |
114 | FEZF1‐AS1 | Zheng‐Lin Ou | 2019 | China | No | 28/28 | 56 | Up-regulation | RNU6B | qRT-PCR | Median | 7 | 60 | Tissue | OS |
125 | lnc-PCTST | Yandong Wang | 2018 | China | 2015–2016 | 24/24 | 48 | Down-regulated | β-Actin | qRT-PCR | Median | 6 | 20 | Tissue | OS |
126 | MACC1-AS1 | Chen Qi | 2019 | China | No | 49/49 | 98 | Up-regulation | β-Actin | qRT-PCR | No | 6 | 100 | Tissue | OS |
136 | XLOC_000647 | Hao Hu | 2018 | China | 2015–2016 | 24/24 | 48 | Down-regulated | β-Actin | qRT-PCR | Median | 7 | 20 | Tissue | OS |
144 | HOTTIP | Ozkan Balcin | 2018 | Turkey | 2006–2014 | 61/39 | 100 | Up-regulation | GAPDH | Q qRT-PCR | No | 7 | 46 | Tissue | OS |
152 | MSC-AS1 | Yunpeng Sun | 2019 | China | No | 23/22 | 45 | Up-regulation | GAPDH | qRT-PCR | Median | 6 | 36 | Tissue | OS |
159 | Sox2ot | Zhonghu Li | 2018 | China | 2012–2016 | 31/30 | 61 | Up-regulation | NO | qRT-PCR | Median | 8 | 50 | Blood | OS |
162 | SPRY4-IT1 | Yue Yaoa | 2018 | China | 2011–2012 | 26/20 | 46 | Up-regulation | GAPDH | qRT-PCR | No | 7 | 60 | Tissue | OS |
169 | GSTM3TV2 | Guangbing Xiong | 2019 | China | No | 100/80 | 180 | Up-regulation | GAPDH & U7 | qRT-PCR | No | 8 | 80 | Tissue | OS |
172 | SNHG15 | X.-B. GUO | 2018 | China | No | 82/89 | 171 | Up-regulation | GAPDH | qRT-PCR | Median | 8 | 60 | Tissue | OS |
185 | HULC | Zheng-Lin Ou | 2019 | China | 2012–2014 | NO | 60 | Up-regulation | GAPDH | qRT-PCR | Median | 8 | 40 | Tissue | OS |
186 | lncRNA-UFC1 | Peng Liu | 2019 | China | 2012–2015 | 19/29 | 48 | Up-regulation | U6 | qRT-PCR | Mean | 8 | 60 | Serum | OS |
187 | FOXP4-AS1 | Xiao-Guang Liu | 2019 | China | No | NO | 112 | Up-regulation | NO | NO | Median | 4 | 50 | Tissue | OS |
188 | PLACT1 | Xiaofan Ren | 2020 | China | 2008–2018 | 83/83 | 166 | Up-regulation | NO | NO | Median | 7 | 60 | Tissue | OS |
189 | ENSG00000254041.1 | Bo Chen | 2020 | China | 2013–2014 | 35/35 | 70 | Up-regulation | GAPDH | qRT-PCR | Median | 4 | 50 | Tissue | OS |